Nanoparticles for co-delivery of osimertinib and selumetinib to overcome osimertinib-acquired resistance in non-small cell lung cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Nanoparticles for co-delivery of osimertinib and selumetinib to overcome osimertinib-acquired resistance in non-small cell lung cancer
Authors
Keywords
Osimertinib, Selumetinib, Reactive Oxygen Species, Prodrug, Non-small Cell Lung Cancer, Acquired resistance
Journal
Acta Biomaterialia
Volume 129, Issue -, Pages 258-268
Publisher
Elsevier BV
Online
2021-05-26
DOI
10.1016/j.actbio.2021.05.018
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
- (2020) G.R. Oxnard et al. ANNALS OF ONCOLOGY
- Overcoming acquired resistance of epidermal growth factor receptor‐mutant non–small‐cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589)
- (2020) Hongjing Zang et al. CANCER
- Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol
- (2020) Hongjing Zang et al. Molecular Oncology
- Excipient-free porphyrin/SN-38 based nanotheranostics for drug delivery and cell imaging
- (2020) Ye Yuan et al. Nano Research
- The entry of nanoparticles into solid tumours
- (2020) Shrey Sindhwani et al. NATURE MATERIALS
- Cytotoxicity of Novel Redox Sensitive PEG2000-S-S-PTX Micelles against Drug-Resistant Ovarian and Breast Cancer Cells
- (2020) N. Basaran Mutlu-Agardan et al. PHARMACEUTICAL RESEARCH
- Metabolic reprogramming and cancer progression
- (2020) Brandon Faubert et al. SCIENCE
- Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers
- (2020) Jun Fang et al. ADVANCED DRUG DELIVERY REVIEWS
- Synergistic effects of Bcl-2 inhibitors with AZD9291 on overcoming the acquired resistance of AZD9291 in H1975 cells
- (2020) Zhongwei Liu et al. ARCHIVES OF TOXICOLOGY
- MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor–mutant lung cancers
- (2020) Jiajia Gu et al. CANCER
- Ultrasound Combined with Core Cross-Linked Nanosystem for Enhancing Penetration of Doxorubicin Prodrug/Beta-Lapachone into Tumors
- (2020) Qianyan Li et al. International Journal of Nanomedicine
- Stimuli-responsive prodrug-based cancer nanomedicine
- (2020) Angel Xie et al. EBioMedicine
- Threatening cancer with nanoparticle aided combination oncotherapy
- (2019) Shruti Rawal et al. JOURNAL OF CONTROLLED RELEASE
- Excipient-free nanodispersion of 7-ethyl-10-hydroxycamptothecin exerts potent therapeutic effects against pancreatic cancer cell lines and patient-derived xenografts
- (2019) Linshi Zhang et al. CANCER LETTERS
- Response to the Combination of Osimertinib and Trametinib in a Patient With EGFR-Mutant NSCLC Harboring an Acquired BRAF Fusion
- (2019) Ibiayi Dagogo-Jack et al. Journal of Thoracic Oncology
- Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
- (2019) Suresh S. Ramalingam et al. NEW ENGLAND JOURNAL OF MEDICINE
- Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
- (2019) Natalie M. Andrews Wright et al. Translational Lung Cancer Research
- ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor‐mutant non–small cell lung cancer cells to osimertinib
- (2019) Yiting Li et al. CANCER
- Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer
- (2018) C Ricordel et al. ANNALS OF ONCOLOGY
- Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies
- (2018) Sun Min Lim et al. CANCER TREATMENT REVIEWS
- Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer
- (2018) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
- Disulfiram Copper Nanoparticles Prepared with a Stabilized Metal Ion Ligand Complex Method for Treating Drug-Resistant Prostate Cancers
- (2018) Wu Chen et al. ACS Applied Materials & Interfaces
- Polymer–drug conjugate therapeutics: advances, insights and prospects
- (2018) Iriny Ekladious et al. NATURE REVIEWS DRUG DISCOVERY
- Integrated block copolymer prodrug nanoparticles for combination of tumor oxidative stress amplification and ROS-responsive drug release
- (2018) Wei Yin et al. BIOMATERIALS
- Sub-100 nm, long tumor retention SN-38-loaded photonic micelles for tri-modal cancer therapy
- (2017) Xixiao Yang et al. JOURNAL OF CONTROLLED RELEASE
- Bioconjugate Therapeutics: Current Progress and Future Perspective
- (2017) Feng Li et al. MOLECULAR PHARMACEUTICS
- Lipid–Drug Conjugate for Enhancing Drug Delivery
- (2017) Danielle Irby et al. MOLECULAR PHARMACEUTICS
- Cancer stem cells revisited
- (2017) Eduard Batlle et al. NATURE MEDICINE
- A New View of Pathway-Driven Drug Resistance in Tumor Proliferation
- (2017) Ruth Nussinov et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- HDAC inhibitor conjugated polymeric prodrug micelles for doxorubicin delivery
- (2017) Suchithra A. Senevirathne et al. Journal of Materials Chemistry B
- Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
- (2017) et al. Cancers
- Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment
- (2016) Puyu Shi et al. CANCER LETTERS
- Self-Assembled Redox Dual-Responsive Prodrug-Nanosystem Formed by Single Thioether-Bridged Paclitaxel-Fatty Acid Conjugate for Cancer Chemotherapy
- (2016) Cong Luo et al. NANO LETTERS
- The role of tumor microenvironment in therapeutic resistance
- (2016) Beomseok Son et al. Oncotarget
- Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models
- (2015) C. A. Eberlein et al. CANCER RESEARCH
- Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors
- (2014) Christian Rolfo et al. CANCER TREATMENT REVIEWS
- Doxorubicin and Lapatinib Combination Nanomedicine for Treating Resistant Breast Cancer
- (2014) Huiyuan Wang et al. MOLECULAR PHARMACEUTICS
- AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
- (2014) D. A. E. Cross et al. Cancer Discovery
- Polymeric Conjugates for Drug Delivery
- (2012) Nate Larson et al. CHEMISTRY OF MATERIALS
- Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
- (2011) H. Cabral et al. Nature Nanotechnology
- Paclitaxel- and lapatinib-loaded lipopolymer micelles overcome multidrug resistance in prostate cancer
- (2011) Feng Li et al. Drug Delivery and Translational Research
- Synthesis and Characterization of Amphiphilic Lipopolymers for Micellar Drug Delivery
- (2010) Feng Li et al. BIOMACROMOLECULES
- Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
- (2009) Dunyaporn Trachootham et al. NATURE REVIEWS DRUG DISCOVERY
- Micellar Delivery of Bicalutamide and Embelin for Treating Prostate Cancer
- (2009) Michael Danquah et al. PHARMACEUTICAL RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started